In this review, we focus on explaining the most recent studies that proposed resistance mechanisms in HER2 mutated breast cancers, along with the potential use of microbiome in combinatorial immunotherapies to treat breast cancer tumour for effective response. This evidence concerns the gene ERBB2 and breast carcinoma.